Spyre Therapeutics, Inc. $SYRE Shares Bought by Candriam S.C.A.

Candriam S.C.A. lifted its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 64.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 404,362 shares of the company’s stock after acquiring an additional 158,332 shares during the quarter. Candriam S.C.A.’s holdings in Spyre Therapeutics were worth $6,777,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Geode Capital Management LLC lifted its holdings in shares of Spyre Therapeutics by 15.8% during the second quarter. Geode Capital Management LLC now owns 1,227,232 shares of the company’s stock valued at $18,373,000 after purchasing an additional 167,669 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Spyre Therapeutics by 300.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 223,320 shares of the company’s stock worth $3,343,000 after buying an additional 167,487 shares during the period. Jefferies Financial Group Inc. lifted its stake in Spyre Therapeutics by 11.2% during the second quarter. Jefferies Financial Group Inc. now owns 1,388,854 shares of the company’s stock valued at $20,791,000 after buying an additional 140,000 shares in the last quarter. Affinity Asset Advisors LLC boosted its holdings in shares of Spyre Therapeutics by 26.0% in the second quarter. Affinity Asset Advisors LLC now owns 606,678 shares of the company’s stock worth $9,082,000 after buying an additional 125,000 shares during the period. Finally, TD Asset Management Inc increased its position in shares of Spyre Therapeutics by 409.5% in the second quarter. TD Asset Management Inc now owns 113,968 shares of the company’s stock worth $1,706,000 after acquiring an additional 91,600 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Mizuho upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Citigroup began coverage on Spyre Therapeutics in a report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 target price for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Spyre Therapeutics in a report on Monday, December 29th. BTIG Research reissued a “buy” rating and set a $70.00 price target on shares of Spyre Therapeutics in a research report on Friday, January 16th. Finally, Wall Street Zen upgraded Spyre Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 16th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $53.88.

Insider Transactions at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $32.80, for a total value of $492,000.00. Following the transaction, the chief executive officer owned 657,540 shares in the company, valued at $21,567,312. The trade was a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 45,000 shares of company stock worth $1,387,500 over the last ninety days. 6.20% of the stock is currently owned by company insiders.

Spyre Therapeutics Stock Down 1.2%

Spyre Therapeutics stock opened at $33.56 on Wednesday. Spyre Therapeutics, Inc. has a 12 month low of $10.91 and a 12 month high of $35.58. The stock has a market cap of $2.60 billion, a P/E ratio of -15.32 and a beta of 3.15. The company’s fifty day simple moving average is $32.89 and its 200-day simple moving average is $24.27.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.